PAG
ABBV icon

Paladin Advisory Group’s AbbVie ABBV Stock Holding History

Paladin Advisory Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-126
Closed -$23.4K – 240
2025
Q2 		$23.4K Buy
+126
New +$23.4K 0.02% 173
2023
Q4 		– Sell
-131
Closed -$19.5K – 229
2023
Q3 		$19.5K Buy
131
+1
+0.8% +$147 0.02% 191
2023
Q2 		$17.5K Buy
130
+1
+0.8% +$147 0.01% 198
2023
Q1 		$20.5K Buy
+129
New +$19.7K 0.02% 194
2022
Q2 		– Sell
-123
Closed -$18.8K – 281
2022
Q1 		$20K Buy
+123
New +$17.9K 0.02% 210

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Paladin Advisory Group's ABBV Position: Q3 2025 in Review

Paladin Advisory Group sold out of AbbVie (ABBV) in Q3 2025, closing a stake of 126 shares — an estimated $23.4K sold.

Paladin Advisory Group first reported a position in ABBV in Q1 2022 and held it in 5 quarters. The position peaked at $23.4K in Q2 2025. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Paladin Advisory Group reported no remaining AbbVie position as of Q3 2025 after selling out during the quarter.
  • Paladin Advisory Group sold 126 AbbVie shares in Q3 2025, an estimated $23.4K.
  • Paladin Advisory Group first reported a position in AbbVie in Q1 2022 and held it in 5 quarters.
  • Paladin Advisory Group's AbbVie position peaked at $23.4K in Q2 2025.
  • 3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Paladin Advisory Group's 13F filing for Q3 2025, filed 5 Nov 2025.